H.R. 946

Summary

H.R. 946, the ORPHAN Cures Act, was introduced in the House on Feb 4, 2025 by Rep. John Joyce (R) with 18 co-sponsors. It last saw action on Feb 6, 2025: Sponsor introductory remarks on measure. (CR H535-536).

Record

Text

H.R. 946 has 18 co-sponsors.

119 HR 946 IH: Optimizing Research Progress Hope And New Cures Act
 U.S. House of Representatives
 2025-02-04
 text/xml
 EN
 Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
 I  119th CONGRESS  1st Session  H. R. 946  IN THE HOUSE OF REPRESENTATIVES   February 4, 2025   Mr. Joyce of Pennsylvania  (for himself,  Mr. Davis of North Carolina ,  Mr. Hern of Oklahoma ,  Mr. Peters ,  Mrs. Miller-Meeks ,  Mr. Keating ,  Mr. Hudson ,  Mr. Thanedar ,  Mr. Bilirakis , and  Mr. Gottheimer ) introduced the following bill; which was referred to the  Committee on Energy and Commerce , and in addition to the Committee on  Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned   A BILL
To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
1.
Short title
This Act may be cited as the   Optimizing Research Progress Hope And New Cures Act   or the   ORPHAN Cures Act  .
2.
Expanding and clarifying the exclusion for orphan drugs under the Drug Price Negotiation Program
Section 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended—
(1)
in paragraph (1), by adding at the end the following new subparagraph:
(C)
Treatment of former orphan drugs
In calculating the amount of time that has elapsed with respect to the approval of a drug or licensure of a biological product under subparagraph (A)(ii) and subparagraph (B)(ii), respectively, the Secretary shall not take into account any period during which such drug or product was a drug described in paragraph (3)(A).
 ; and
(2)
in paragraph (3)(A)—
(A)
by striking  only one rare disease or condition  and inserting  one or more rare diseases or conditions ; and
(B)
by striking  such disease or condition  and inserting  one or more rare diseases or conditions (as such term is defined in section 526(a)(2) of the Federal Food, Drug, and Cosmetic Act) .

Tracker

The tracker indicates the progress of this legislation as it moves through the legislative process.

CRS Summary

The summaries are the Congressional Research Service’s, one per stage. Read them in full.

Sponsors

Rep. John Joyce (R) sponsors H.R. 946, and 18 members have co-sponsored it, 9 of them from the day it was introduced.

John Joyce

Rep. · R–PA-13 · Sponsor

Introduced Feb 4, 2025

Gus Bilirakis

Rep. · R–FL-12 · Co-sponsor

Joined Feb 4, 2025 · Original

Donald Davis

Rep. · D–NC-1 · Co-sponsor

Joined Feb 4, 2025 · Original

Josh Gottheimer

Rep. · D–NJ-5 · Co-sponsor

Joined Feb 4, 2025 · Original

Kevin Hern

Rep. · R–OK-1 · Co-sponsor

Joined Feb 4, 2025 · Original

Richard Hudson

Rep. · R–NC-9 · Co-sponsor

Joined Feb 4, 2025 · Original

William Keating

Rep. · D–MA-9 · Co-sponsor

Joined Feb 4, 2025 · Original

Mariannette Miller-Meeks

Rep. · R–IA-1 · Co-sponsor

Joined Feb 4, 2025 · Original

Scott Peters

Rep. · D–CA-50 · Co-sponsor

Joined Feb 4, 2025 · Original

Shri Thanedar

Rep. · D–MI-13 · Co-sponsor

Joined Feb 4, 2025 · Original

Show 10 of 19 rows

PreviousNext

Committees

H.R. 946 went before 2 committees: Ways and Means and Energy and Commerce.

Ways and Means

Ways and Means

Referred To · Feb 4, 2025 · 1,160 Bills

Energy and Commerce

Energy and Commerce

Referred To · Feb 4, 2025 · 1,636 Bills

Actions

H.R. 946 has taken 3 actions since Feb 4, 2025, the latest on Feb 6, 2025.

Votes

H.R. 946 has not gone to a roll call.

Related bills

1 bill is related to H.R. 946.

S 1862ORPHAN Cures ActMay 22, 2025 · Read twice and referred to the Committee on Finance. (text: CR S3119) · Related bill

Show 1 of 1 row

PreviousNext

Titles

H.R. 946 goes by 4 titles, 2 of them short titles.

• ORPHAN Cures Act — Display Title
• ORPHAN Cures Act — Short Title(s) as Introduced
• Optimizing Research Progress Hope And New Cures Act — Short Title(s) as Introduced
• To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program. — Official Title as Introduced

Lobbying

59 clients hired 53 firms and 322 registered lobbyists who named H.R. 946 in 296 quarterly filings, 2025 to 2026. Reported under the Lobbying Disclosure Act; a filing’s income covers everything its registrant worked that quarter, so the amounts below are the filings’, not this bill’s.

Filed under Medicare/Medicaid, Health Issues, Taxation/Internal Revenue Code, Trade (domestic/foreign), Budget/Appropriations, Pharmacy, Copyright/Patent/Trademark, Medical/Disease Research/Clinical Labs.

Clients

Who paid to be heard, by how many filings named the bill. The 20 that filed most often, of 59.

Firms

Registrants who filed on the bill, by filings.

Lobbyists

Named on the filings that cite the bill. The 20 named most often, of 322.

Filings

The documents themselves, on the Senate’s Lobbying Disclosure site, largest reported first.

Classification

The Congressional Research Service files H.R. 946 under Health, one of its 31 policy areas, and gives it 3 legislative subjects.

CRS Subjects

CRS assigns every bill one policy area from its 31; H.R. 946’s is Health.

Legislative Subjects

H.R. 946 carries 3 of CRS’s legislative subjects, from Health care costs and insurance to Prescription drugs.

Source: congress.gov · legiscan.com